Literature DB >> 15756499

[Selective inhibition of T-cell activation with fusion protein CTLA4lg as a new treatment option for rheumatoid arthritis].

K Krüger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15756499     DOI： 10.1007/s00393-005-0620-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  2 in total

1.  CTLA-4-Ig regulates tryptophan catabolism in vivo.

Authors:  Ursula Grohmann; Ciriana Orabona; Francesca Fallarino; Carmine Vacca; Filippo Calcinaro; Alberto Falorni; Paola Candeloro; Maria L Belladonna; Roberta Bianchi; Maria C Fioretti; Paolo Puccetti
Journal:  Nat Immunol       Date:  2002-09-30       Impact factor: 25.606

2.  Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.

Authors:  Larry W Moreland; Rieke Alten; Filip Van den Bosch; Thierry Appelboom; Marc Leon; Paul Emery; Stanley Cohen; Michael Luggen; William Shergy; Isaac Nuamah; Jean-Claude Becker
Journal:  Arthritis Rheum       Date:  2002-06
  2 in total
  1 in total

Review 1.  Abatacept for rheumatoid arthritis.

Authors:  Lara Maxwell; Jasvinder A Singh
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.